# Opdivo

Type: Product

Source: Finance Intelligence Brief — https://getfinancebrief.com/entity/opdivo
Canonical HTML page: https://getfinancebrief.com/entity/opdivo

## Recent coverage (1 stories)

### AstraZeneca, BMS $400B Merger Talk Sparks Pharma M&A Frenzy
2026-08-02 23:37:40 · Sentiment: Neutral · Impact: 9/10 · Sources: 2

The speculative $400 billion merger would rank among the largest ever, offering BMS stockholders an exit from patent headwinds and giving AZN a US listing boost. However, financing structure and antitrust hurdles present major risks.
Full story: https://getfinancebrief.com/story/astrazeneca-bms-400b-merger-talks-markets

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getfinancebrief.com/guides/methodology for the full editorial methodology.